Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

ill be to pursue a larger Phase II study to optimize dosing regimens. Novo Nordisk A/S holds an exclusive license to the E1-I.N.T.(TM) product and can further develop and commercialize this product in accordance with the terms of the companies' amended license agreement as previously announced July 17, 2006.

In addition, these clinical data further support and validate the potential of Transition's other gastrin based therapies to provide type 2 diabetes patients with sustained improvement in glucose control. Transition holds the exclusive rights to a series of proprietary gastrin based combination therapies including GLP1-I.N.T.(TM) (a combination of gastrin analogue, G1, and a GLP-1 analogue) and combination therapies of gastrin and DPP-IV inhibitors. Based on these encouraging findings, Transition is accelerating the development of these combination gastrin-based therapies into clinical trials.

Conference Call Details:

Transition will host a conference call to be held at 5:00pm EST on Thursday, June 28th, 2007. Dr. Sherwyn Schwartz from San Antonio Texas who was the lead investigator in this study will be available to answer any questions. The conference call can be accessed by dialing 1 (800) 633-8548. International callers are advised to dial (212) 676-5241. To participate, please dial the conference number 15 minutes prior to the beginning of the call. A replay of the conference call will be available until July 6, 2007 by visiting Transition's website www.transitiontherapeutics.com.

About the Study Design

This exploratory Phase IIa clinical study for E1-I.N.T.(TM) was a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of daily E1-I.N.T.(TM) treatments for 4 weeks with a 6-month follow-up in type 2 diabetes patients. The E1-I.N.T.(TM) treatment consisted of a combination of two agents, G1 and E1. All patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
(Date:4/20/2015)... , April 20, 2015 Research published today ... of Sciences (PNAS) demonstrates that technology invented ... Casey Eye Institute can improve the ... Optical coherence tomography (OCT) angiography could largely replace ... diseases. OHSU researchers found that OCT ...
(Date:4/20/2015)... BILLERICA, Mass. , April 20, 2015 /PRNewswire/ ... tools for cell metabolism research, introduces the XFp ... a unique real-time assay on live cells that ... one-hour test measures both the mitochondrial and glycolytic ... values with metabolic activity under stressed conditions, induced ...
Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5New XFp Cell Energy Phenotype Test Determines Metabolic Potential 2New XFp Cell Energy Phenotype Test Determines Metabolic Potential 3
... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:4/21/2015)... Lifeguard Master is out with their new ... listed on the Lifeguard Master website and are in stock. ... want a quality and flexible product during their rescue efforts. ... color Spider Straps are some of the most popular items ... sturdy, heavy nylon” , The Spider Straps are rated superior ...
(Date:4/21/2015)... Dr. Zain Kadri, a Beverly Hills plastic surgery ... a close look at the rise of plastic surgery among ... both Dr. Kadri’s website and RedOrbit , is titled ... of the Selfie.” According to Dr. Kadri, who offers exceptional ... of A-list patients, the trend of taking selfies has been ...
(Date:4/21/2015)... TX (PRWEB) April 21, 2015 ... from a prestigious Illinois university for a second ... units (NICUs) more conducive to newborn infants’ cognitive ... top three NICU problems we have identified through ... care professionals,” said George Hutchinson, Invictus Medical’s Chief ...
(Date:4/20/2015)... April 20, 2015 Construction has ... in Stuarts Draft, an independent, nonprofit community hospital ... Waynesboro, Virginia. The project was an ongoing collaboration ... Draft facility is expected to provide additional employment ... Stuarts Draft Highway, the new facility features physician ...
(Date:4/20/2015)... NAPW honors Suzanne ... the Year. Ms. Webb is recognized with this prestigious ... networking organization of professional women in the country, spanning ... Professional Women is a powerfully vibrant networking community with ... “We are like an Angie’s List for surgeons and ...
Breaking Medicine News(10 mins):Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 2Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 3Health News:New Spider Straps for Spine Boards are Introduced for Easy, Fast, and Convenient Use 4Health News:Beverly Hills Plastic Surgery Expert Dr. Zain Kadri Releases Thought-Provoking New Infographic 2Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Augusta Health Construction Wraps Up at Stuarts Draft 2Health News:National Association of Professional Women Announces Suzanne Webb, Chief Executive Officer at Exclusive Surgeries Network, LLC, a 2015 Professional Woman of the Year 2
... cause employers to abandon benefits, study finds , , FRIDAY, April ... insurance for employees increased more for small U.S. businesses than ... small businesses have not stopped offering the benefit, a new ... Corp., of more than 2,500 small, medium and large companies ...
... delve into some of the crucial issues surrounding death by ... in the joint University of Adelaide/IMVS Centre for Neurological Diseases, ... brain and the reasons why brain tumours or strokes become ... brain works, and this new research will help to unlock ...
... 2008 Companies align,commercial and portfolio management employees ... sales volume of $10 to 20 billion, on ... commercialization team along,with approximately eight portfolio managers. At ... four to three, commercial to,portfolio management staff, according ...
... CHAPEL HILL Young children who lead inactive lifestyles are ... heart disease, with that degree of danger emerging as early ... researchers at the University of North Carolina at Chapel Hill. ... access journal Dynamic Medicine, looked at a group of children ...
... 54 million American,adults have prediabetes, but many of ... and all of its health complications thanks to ... Optimal Health,Company. It is estimated that 60 percent ... choices., "When someone is pre-diabetic, they don,t ...
... but not mother,s, weight and elevated enzymes , , THURSDAY, ... early-onset obesity are at increased risk for elevated liver ... , Researchers evaluated 1,732 children, average age 42, of ... of families in Framingham, Mass. The researchers found that ...
Cached Medicine News:Health News:Small Firms Shoulder Burden of Increasing Health Costs 2Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2Health News:Kronos Optimal Health Company Aims to Stop Diabetes Before It Starts 2Health News:Dads' Early-Onset Obesity Linked to Liver Disease in Kids 2
Aluminum english and metric ruler. 1 3/8 inche wide....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: